Brady L Stein, Stephen T Oh, Dmitriy Berenzon, Gabriela S Hobbs, Marina Kremyanskaya, Raajit K Rampal, Camille N Abboud, Kenneth Adler, Mark L Heaney, Elias J Jabbour, Rami S Komrokji, Alison R Moliterno, Ellen K Ritchie, Lawrence Rice, John Mascarenhas, Ronald Hoffman
Polycythemia vera (PV) is a chronic myeloproliferative neoplasm that is associated with a substantial symptom burden, thrombohemorrhagic complications, and impaired survival. A decade after the seminal discovery of an activating mutation in the tyrosine kinase JAK2 in nearly all patients with PV, new treatment options are finally beginning to emerge, necessitating a critical reappraisal of the underlying pathogenesis and therapeutic modalities available for PV. Herein, we comprehensively review clinical aspects of PV including diagnostic considerations, natural history, and risk factors for thrombosis...
November 20, 2015: Journal of Clinical Oncology